Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib for recurrent uterine malignancies after failure of second-line or later chemotherapy
ChiCTR1800018965Phase 2Recruiting
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jun 2018
- Modality
- Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Rivoceranib in uterine cancer, endometrial cancer (EC), endometrial carcinosarcoma and 3 more, sponsored by Fudan University Shanghai Cancer Center. Primary endpoints: Overall response rate and Progression-free survival. Started Jun 2018; status: recruiting.
02
Drugs
Rivoceranib
03
Conditions
uterine cancerendometrial cancer (EC)endometrial carcinosarcomauterine leiomyosarcoma (uLMS)Endometrial Sarcoma (ESS)
Beyond the preview
Go deeper on ChiCTR1800018965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018965.